^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SOX9 overexpression

    i
    Other names: SOX9, SRY-Box Transcription Factor 9, Transcription Factor SOX-9, SRY-Box 9, SRY (Sex-Determining Region Y)-Box 9 Protein, Campomelic Dysplasia Autosomal Sex-Reversal, SRY (Sex Determining Region Y)-Box 9, SRY (Sex Determining Region Y)-Box9, SRY-Related HMG-Box Gene 9, SRXY10, SRXX2, CMPD1, SRA1, CMD1
    Entrez ID:
    6662
    Related biomarkers:
    Expression
    1year
    Long noncoding RNA steroid receptor RNA activator 1 inhibits proliferation and glycolysis of esophageal squamous cell carcinoma. (PubMed, World J Gastrointest Oncol)
    SRA1 inhibits the oncogenicity of ESCC via miRNA-363-5p/LHPP axis. The SRA1/miRNA-363-5p/LHPP pathway may be a therapeutic target for ESCC.
    Journal
    |
    SOX9 (SRY-Box Transcription Factor 9)
    |
    SOX9 overexpression • SOX9 expression
    almost2years
    MFAP5 Strengthened the Stem Cell Features of Non-small Cell Lung Cancer Cells by Regulating the FBW/Sox9 Axis. (PubMed, Curr Pharm Biotechnol)
    MFAP5 maintained the stem cell features of non-small cell lung cancer cells by modulating FBW7/Sox9 axis.
    Journal
    |
    FBXW7 (F-Box And WD Repeat Domain Containing 7) • SOX9 (SRY-Box Transcription Factor 9)
    |
    SOX9 overexpression • SOX9 expression
    almost2years
    Exposure of piperlongumine attenuates stemness and epithelial to mesenchymal transition phenotype with more potent anti-metastatic activity in SOX9 deficient human lung cancer cells. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    This has been the first study to discover the high expression of SOX9 supporting the survival of LCC, whereas its inhibition induces higher sensitivity to PIP treatment. This study concludes a newer therapeutic agent (PIP) with promising anticancer activity against LCC by escalating ROS and attenuating MMP, stemness, and EMT.
    Journal • Metastases
    |
    SOX9 (SRY-Box Transcription Factor 9)
    |
    SOX9 overexpression • SOX9 expression
    almost2years
    Hypoxia promotes non-small cell lung cancer cell stemness, migration, and invasion via promoting glycolysis by lactylation of SOX9. (PubMed, Cancer Biol Ther)
    Hypoxia induced the lactylation of SOX9 to promote stemness, migration, and invasion via promoting glycolysis. The findings suggested that targeting hypoxia may be an effective way for NSCLC treatment and reveal a new mechanism of hypoxia in NSCLC.
    Journal
    |
    SOX9 (SRY-Box Transcription Factor 9)
    |
    SOX9 overexpression • SOX9 expression
    2years
    SOX9 promotes the invasion and migration of lung adenocarcinoma cells by activating the RAP1 signaling pathway. (PubMed, BMC Pulm Med)
    Overexpression of SOX9 in LUAD can significantly activate the RAP1 signaling pathway and promote cell invasion and migration.
    Journal
    |
    SOX9 (SRY-Box Transcription Factor 9)
    |
    SOX9 overexpression • SOX9 expression
    2years
    Upregulation of SOX9 promotes the self-renewal and tumorigenicity of cervical cancer through activating the Wnt/β-catenin signaling pathway. (PubMed, FASEB J)
    In addition, SOX9 could transcriptional inhibit DKK1 and activate FZD10 and MYC by binding to their promoters to affect the Wnt/β-catenin pathway. These results demonstrated SOX9 regulated the self-renewal and tumorigenicity of cervical cancer through Wnt/β-catenin pathway by directly transcriptional activation of FZD10, MYC and transcriptional inhibition of DKK1.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • DKK1 (dickkopf WNT signaling pathway inhibitor 1) • SOX9 (SRY-Box Transcription Factor 9) • FZD10 (Frizzled Class Receptor 10)
    |
    MYC expression • SOX9 overexpression • SOX9 expression
    over2years
    SOX9/NFIA promotes human ovarian cancer metastasis through the Wnt/β-catenin signaling pathway. (PubMed, Pathol Res Pract)
    In conclusion, this study shows that SOX9 has a promotional effect on human ovarian cancer and that SOX9 promotes the metastasis of tumors by upregulating NFIA and activating on a Wnt/β-catenin signal pathway. SOX9 could be a novel focus for earlier diagnosis, therapy and prospective evaluation in ovarian cancer.
    Journal
    |
    CDH1 (Cadherin 1) • MUC16 (Mucin 16, Cell Surface Associated) • SOX2 • SOX9 (SRY-Box Transcription Factor 9) • CDH2 (Cadherin 2)
    |
    CDH1 expression • SOX9 overexpression • SOX9 expression
    over2years
    Expression of circ-PHC3 enhances ovarian cancer progression via regulation of the miR-497-5p/SOX9 pathway. (PubMed, J Ovarian Res)
    Taken together, our findings suggest that circ-PHC3 enhances OC progression through functioning as an miR-497-5p sponge to promote SOX9 expression, supporting its potential as a promising candidate target for OC therapy.
    Journal
    |
    SOX9 (SRY-Box Transcription Factor 9) • MIR497 (MicroRNA 497)
    |
    SOX9 overexpression • SOX9 expression
    over2years
    Comprehensive analysis, immune, and cordycepin regulation for SOX9 expression in pan-cancers and the matched healthy tissues. (PubMed, Front Immunol)
    Moreover, SOX9 might play an important role in tumor genesis and development by participating in immune infiltration. Altogether, SOX9 could be a biomarker for diagnostics and prognostics for pan-cancers and an emerging target for the development of anticancer drugs.
    Journal • Pan tumor
    |
    SOX9 (SRY-Box Transcription Factor 9) • YBX1 (Y-Box Binding Protein 1)
    |
    SOX9 overexpression • SOX9 expression
    |
    cordycepin (OVI-123)
    almost3years
    SOX9 and HMGB3 co-operatively transactivate NANOG and promote prostate cancer progression. (PubMed, Prostate)
    These findings showed a novel SOX9/HMGB3/NANOG regulatory mechanism, deregulation of which played important roles in PCa progression.
    Journal
    |
    SOX9 (SRY-Box Transcription Factor 9) • NANOG (Nanog Homeobox)
    |
    SOX9 overexpression • SOX9 expression